Abstract:Abstract The rise of Targeted Protein Degradation (TPD) is rapidly changing perceptions about therapeutic target druggability and is rewriting many preconceived notions on drug design. However, the majority of monovalent molecular glue and heterobifunctional degraders in clinical and preclinical development rely predominantly on the recruitment of a single E3 ligase, Cereblon. Arising resistance, toxicities and restricted Protein-of-Interest scope may limit clinical potential, highlighting the need to uncover novel TPD mechanisms. To expand the potential of this modality, we have developed SITESEEKER®, a screening technology operating at substantially greater magnitude of complexity than extant target discovery platforms. SITESEEKER® utilizes computationally-derived encoded mini-protein fragments with huge shape diversity to systematically identify novel degrader mechanisms and define functionally-active binding sites on targets. SITSEEKER® allows for the discovery of targets that may be missed through traditional gene editing or knockdown approaches and can additionally provide valuable mechanistic insights that help to inform, unlock and truncate the path from target ID to drug discovery. We describe the identification of a cache of degrader motifs which showcase the breadth of proteome space yet to be explored within TPD. Moreover, we identify peptide motifs capable of driving degradation in a selective manner with potential to be translated into tissue- or cancer-selective degraders. The functional dependencies of prioritized degraders have been mapped to their cognate E3 ligase using combinatorial screening, giving rise to a number of E3 ligases with potential to be hijacked for TPD. PhoreMost is progressing a pipeline of monovalent and heterobifunctional oncology degrader programs arising from its platform. We demonstrate the effective hijacking of selected E3 ligases, identified by SITESEEKER®, through the discovery of high affinity small molecule binders and subsequent discovery of efficient heterobifunctional degraders against selected Proteins-of-Interest. Citation Format: Christian Dillon. Systematic identification of novel targeted protein degradation mechanisms using SITESEEKER® technology [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 6052.

Exploring the target scope of KEAP1 E3 ligase-based PROTACs

PROTACs: an Emerging Targeting Technique for Protein Degradation in Drug Discovery

Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation

Design and characterization of a heterobifunctional degrader of KEAP1

Co-opting the E3 ligase KLHDC2 for targeted protein degradation by small molecules

Principles of paralog-specific targeted protein degradation engaging the C-degron E3 KLHDC2

Targeted Protein Degradation: Current and Emerging Approaches for E3 Ligase Deconvolution

Exploiting the Cullin E3 Ligase Adaptor Protein SKP1 for Targeted Protein Degradation

Discovery of E3 Ligase Ligands for Target Protein Degradation

DCAF1-based PROTACs with activity against clinically validated targets overcoming intrinsic- and acquired-degrader resistance

Leveraging dual-ligase recruitment to enhance degradation via a heterotrivalent PROTAC

Targeted protein degradation: expanding the toolbox

Recent advances in targeted protein degraders as potential therapeutic agents

In Vivo Target Protein Degradation Induced by PROTACs Based on E3 Ligase DCAF15

E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones

Targeting UBE2C for Degradation by Bioprotacs Based on Bacterial E3 Ligase

Abstract 6052: Systematic identification of novel targeted protein degradation mechanisms using SITESEEKER® technology

Electrophilic PROTACs that degrade nuclear proteins by engaging DCAF16

Discovery of electrophilic degraders that exploit SNAr chemistry

Drugging Protein Tyrosine Phosphatases through Targeted Protein Degradation

PROTACs: A Novel Strategy for Cancer Drug Discovery and Development